(2) the withdrawal of "Compliance Policy Guide Sec. 690.700 *Salmonella* Contamination of Dry Dog Food." The enforcement policy in the CPG supersedes the policies articulated in 21 CFR 500.35 and CPG Sec. 690.700.

#### **II. Comments**

Interested persons may submit either electronic comments regarding the CPG to *http://www.regulations.gov* or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments. Identify comments with the docket number found in brackets in the heading of this document. Received comments may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at *http:// www.regulations.gov.* 

#### **III. Electronic Access**

Persons with access to the Internet may obtain the CPG at either http:// www.fda.gov/ora/compliance\_ref/cpg/ default.htm or at http:// www.regulations.gov. Use the FDA Web site listed in the previous sentence to find the most current version of the CPG.

Dated: July 10, 2013.

# Leslie Kux,

Assistant Commissioner for Policy. [FR Doc. 2013–16975 Filed 7–15–13; 8:45 am] BILLING CODE 4160–01–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

#### **ACTION:** Notice.

**SUMMARY:** The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

# FOR FURTHER INFORMATION CONTACT:

Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301– 496–7057; fax: 301–402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of patent applications.

#### Islet Beta Cell Only M3 Muscarinic Acetylcholine Receptor Knockout Mouse

Description of Technology: Researchers at NIH have developed islet beta cell M3 muscarinic acetylcholine receptor knockout mouse. The mice were generated by crossing floxed mouse M3 muscarinic acetylcholine receptor mice with mice in which Cre recombinase was controlled by the betacell specific rat insulin promoter (RIP-Cre mice).

Potential Commercial Applications: Study of the physiological role of betacell M3 muscarinic receptors in the regulation of glucose homeostasis and insulin release in vivo.

*Competitive Advantages:* Allows for study of the role of the M3 receptors in the pancreas without whole body effects confounding the results.

*Development Stage:* In vivo data available (animal)

Inventor: Jürgen Wess, Ph.D. (NIDDK) Publication: Gautam D, et al. A critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab. 2006 Jun;3(6):449–61. [PMID 16753580]

*Intellectual Property:* HHS Reference No. E–452–2013/0—Research Tool. Patent protection is not being pursued for this technology.

Licensing Contact: Jaime M. Greene, M.S.; 301–435–5559; greenejaime@mail.nih.gov.

#### Transgenic Mice With Constitutively Active M3 Muscarinic Receptor in Islet Beta Cells

Description of Technology: Q490L point mutation was introduced into the rat M3 muscarinic receptor cDNA to confer persistent, constitutive (ligandindependent) activity. Expression of the M3 receptor mutant was placed under the control of a 650 bp fragment of the rat insulin promoter II (RIP II) to limit expression to the islet beta cell.

*Potential Commercial Applications:* Diabetes research, especially type II Diabetes.

*Competitive Advantages:* Beneficial metabolic effects of this mouse model include high basal insulin secretion, improved glucose tolerance, increased serum insulin, and resistance to high-fat diet-induced glucose intolerance and hyperglycemia.

*Development Stage:* In vivo data available (animal)

Inventor: Jürgen Wess, Ph.D. (NIDDK) Publication: Gautam D, et al. Beneficial metabolic effects caused by persistent activation of beta-cell M3 muscarinic acetylcholine receptors in transgenic mice. Endocrinology. 2010 Nov;151(11):5185–94. [PMID 20843999]

*Intellectual Property:* HHS Reference No. E–453–2013/0—Research Tool. Patent protection is not being pursued for this technology.

*Licensing Contact:* Jaime M. Greene, M.S.; 301–435–5559;

greenejaime@mail.nih.gov.

# Transgenic Mice Overexpressing Islet Beta Cell M3 Muscarinic Acetylcholine Receptors

Description of Technology: Researchers at NIH have generated transgenic mice in which the M3 muscarinic receptor is overexpressed in pancreatic beta cells. This was done by placing the receptor gene under the control of the 650 bp rat insulin promoter II (RIP II). The resulting mice show a pronounced increase in glucose tolerance and enhanced plasma insulin levels. Strikingly, these mutant mice were resistant to diet-induced glucose intolerance and hyperglycemia.

Potential Commercial Applications: Diabetes research, especially type II Diabetes.

*Competitive Advantages:* These transgenic mice overexpress the M3 muscarinic acetylcholine receptor only in pancreatic beta cells but notably are resistant to diet-induced glucose intolerance and hyperglycemia.

*Development Stage:* In vivo data available (animal).

*Inventor:* Jürgen Wess, Ph.D. (NIDDK). *Publication:* Gautam D, et al. A

critical role for beta cell M3 muscarinic acetylcholine receptors in regulating insulin release and blood glucose homeostasis in vivo. Cell Metab. 2006 Jun;3(6):449–61. [PMID 16753580].

*Intellectual Property:* HHS Reference No. E–455–2013/0—Research Tool. Patent protection is not being pursued for this technology.

Licensing Contact: Jaime M. Greene, M.S.; 301–435–5559; groopoinimo@mail.nih.gov

greenejaime@mail.nih.gov.

# An Improved System for Production of Recombinant Baculovirus

Description of Technology: Baculoviruses have been used for decades to produce proteins in insect cell hosts. Current systems for generating recombinant baculovirus have several shortcomings which prevent their easy use in highthroughput applications. The present invention discloses an improved system to quickly and efficiently generate recombinant baculoviruses which produce recombinant proteins. In the new system, the baculovirus transfer vector, transposition helper plasmid and E. coli strain carrying the bacmid DNA were modified to eliminate the need for screening positive clones and improve the efficiency of baculovirus production. Taken together, these improvements permit facile highthroughput recombinant baculovirus production at reduced cost and improved speed over the currently available systems.

Potential Commercial Applications:High-throughput protein

production

• Generation of virus-like particles in insect cells

*Competitive Advantages:* 

• Elimination of background plasmid DNA during recombinant baculovirus production

• Elimination of nonproductive transposition events leading to false positives

• Lower cost production of baculovirus

• Increased speed of baculovirus production (allowing high-throughput production with limited screening)

• Higher efficiency cloning of baculovirus constructs

Development Stage:

Prototype

• Pilot

• In vitro data available Inventor: Dominic Esposito (NCI).

*Intellectual Property:* HHS Reference No. E–287–2012/0—Research Tool. Patent protection is not being pursued for this technology.

*Related Technology:* HHS Reference No. E–164–2011—Combinatorial Cloning Platform.

*Licensing Contact:* Susan Ano, Ph.D.; 301–435–5515; *anos@mail.nih.gov.* 

Dated: July 9, 2013.

#### Richard U. Rodriguez,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 2013–16947 Filed 7–15–13; 8:45 am]

BILLING CODE 4140-01-P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

# National Center for Complementary & Alternative Medicine; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Center for Complementary and Alternative Medicine Special Emphasis Panel RFA–AT–11–011: Mechanistic Research on CAM Natural Products (R01).

Date: September 13, 2013.

*Time:* 7:00 a.m. to 5:00 p.m.

Agenda: To review and evaluate grant applications.

*Place:* Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

*Contact Person:* Martina Schmidt, Ph.D., Scientific Review Officer, Office of Scientific Review, National Center for Complementary & Alternative Medicine, NIH, 6707 Democracy Blvd., Suite 401, Bethesda, MD 20892, 301–594–3456,

schmidma@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.213, Research and Training in Complementary and Alternative Medicine, National Institutes of Health, HHS)

Dated: July 10, 2013.

#### Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–16940 Filed 7–15–13; 8:45 am] BILLING CODE 4140–01–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### Center for Scientific Review; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. *Name of Committee:* Center for Scientific Review Special Emphasis Panel; Member Conflict: Risk, Prevention and Health Behavior.

#### Date: July 24, 2013.

Time: 10:30 a.m. to 12:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (Telephone Conference Call).

Contact Person: Kristen Prentice, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 3112, MSC 7808, Bethesda, MD 20892, 301–496– 0726, prenticekj@mail.nih.gov.

This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS)

Dated: July 10, 2013.

#### Michelle Trout,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–16939 Filed 7–15–13; 8:45 am] BILLING CODE 4140–01–P

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### **National Institutes of Health**

# National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Neurological Disorders and Stroke Special Emphasis Panel; EUREKA.

*Date:* August 14, 2013.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Melrose Hotel, 2430 Pennsylvania Ave. NW., Washington, DC 20037.

Contact Person: Natalia Strunnikova,

Ph.D., Scientific Review Officer, Scientific